Stock LYTIX LYTIX BIOPHARMA
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Lytix Biopharma

Equities

LYTIX

NO0010405780

Market Closed - Oslo Bors
Other stock markets
 15:45:00 10/05/2024 BST 		5-day change 1st Jan Change
5.48 NOK +0.37% Intraday chart for Lytix Biopharma -6.48% +12.76%
04-25 Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity CI
04-10 Lytix Biopharma to Raise Up to NOK55 Million via Share Offering MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Correction in the notice of Annual General Meeting in Lytix Biopharma AS
AQ
Lytix Biopharma AS: Notice of Annual General Meeting on 14 May 2024
AQ
Lytix Biopharma AS: Annual Report for 2023
AQ
Lytix Biopharma AS - Share issue pursuant to board authorisation
AQ
Lytix Biopharma AS - Mandatory notification of trade by Primary Insiders and close associates
AQ
Lytix Biopharma AS - Minutes of extraordinary general meeting and final results of share offering
AQ
Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity
AQ
Lytix Biopharma AS - Preliminary results in the share offering
AQ
Lytix Biopharma AS - Last day of the Application Period
AQ
Lytix Biopharma : CEO Presentation and Q&A with Redeye AB
PU
Lytix Biopharma presents third quarter 2023 results
AQ
Lytix Biopharma presenting at major investor conferences in London and Stockholm in November
AQ
Encouraging preliminary data from Lytix Biopharma's ATLAS-IT-05 study presented at ESMO 2023
AQ
Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from 'SkatteFUNN'
AQ
Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting
AQ
Lytix Biopharma presents first half and second quarter 2023 results
AQ
Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial
AQ
Lytix Biopharma : Redeye interviewed Øystein Rekdal about Lytix and his role as CEO
PU
Lytix Biopharma's licensing partner Verrica Pharmaceuticals Inc. reports interim Phase 2 data with LTX-315
AQ
Lytix Biopharma announces that Verrica Pharmaceuticals Inc. will present clinical results from their ongoing Phase II clinical study with LTX-315 (VP-315) at the AAD 2023 Innovation Academy Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LYTIX Stock
  4. News Lytix Biopharma
  5. Press Releases